Printer Friendly

Browse Cysteamine topic

 

Articles

1-26 out of 26 article(s)
Title Author Type Date Words
Ireland : Horizon Pharma plc Completes Sale of European Marketing Rights for PROCYSBI (cysteamine bitartrate) delayed-release capsules and QUINSAIR (levofloxacin nebuliser solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farmaceutici S. Jun 24, 2017 230
Multimedia Now Available: Raptor Pharmaceutical's PROCYSBI(TM) Receives FDA Approval for the Treatment of Nephropathic Cystinosis. May 1, 2013 1660
Raptor Pharmaceutical's PROCYSBI(TM) Receives FDA Approval for the Treatment of Nephropathic Cystinosis. Apr 30, 2013 1617
Raptor Pharmaceutical's PROCYSBI(TM) Receives FDA Approval for the Treatment of Nephropathic Cystinosis. Apr 30, 2013 1625
Radiolabeling and Bioevaluation of Dextran Cysteamine Mannose for Sentinel Lymph Node Detection. Dar, Ume Kalsoom; Khan, Irfan Ullah; Javed, Muhammad; Ali, Muhammad; Hyder, Syed Waqar; Murad, Sohai Report Aug 31, 2012 2814
Raptor Pharmaceutical Submits NDA for RP103. May 1, 2012 634
Raptor gives update on Phase III study of DR Cysteamine for nephropathic cystinosis. Jun 8, 2011 335
Raptor to reopen enrollment in pivotal Phase III clinical trial of DR Cysteamine. Feb 15, 2011 274
Raptor completes enrollment in Phase III trial of DR Cysteamine in cystinosis. Jan 25, 2011 220
Raptor Pharmaceutical Corp begins Phase 2 clinical trial of DR Cysteamine for Huntington's Disease. Nov 9, 2010 178
RAPTOR ENROLLS FIRST PATIENT IN DR CYSTEAMINE PHASE 3. Jul 30, 2010 981
Sigma-Tau Pharmaceuticals Cysteamine Eye Drop NDA Accepted for Filing. May 17, 2010 909
Raptor says Phase IIa NASH study meets primary endpoints. Clinical report May 5, 2010 383
Raptor Pharmaceutical Corp. to Present Cystinosis Research at Lysosomal Disease Network's 2010 WORLD Symposium; - Forms European Subsidiary, Raptor Pharmaceuticals Europe BV. Feb 10, 2010 1268
Raptor announces publication of DR Cysteamine Phase IIa results. Jan 11, 2010 228
Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis; - Potential to Improve Treatment with Less Frequent Administration and Better Tolerability. Jan 11, 2010 1468
Carbon Nanotubes Detect Cysteamine in Biological Compounds. Dec 31, 2009 226
Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis. Nov 23, 2009 1417
Raptor completes Phase IIb study of DR Cysteamine in cystinosis. Clinical report Nov 23, 2009 255
Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH). Oct 12, 2009 1356
Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis. Jun 1, 2009 1283
Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH). Feb 5, 2009 1231
Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease. Nov 10, 2008 1478
Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH). Oct 20, 2008 1257
Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease. Jul 16, 2008 1288
Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline. Mar 19, 2008 1462

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters